摘要
目的通过微流控平台技术检测非小细胞肺癌(NSCLC)患者外周血肿瘤循环细胞(CTC)并与常规肿瘤标志物检测进行对比,探讨CTC检测用于NSCLC早期诊断的作用。方法采用Celltracker CMFDA染色标记肿瘤细胞,进行细胞掺入并统计细胞回收率;收取65例临床确诊的NSCLC患者的血液样本,通过CTC检测和化学发光法检测肿瘤标记物(/NSE/CEA/Cyfra21-1)并进行对比分析。结果微流控平台对CTC的捕获效率为(85.0±1.5)%,在65例NSCLS患者样本中,传统肿瘤标记物的检出为34例,检出率52.3%,CTC检测的检出率为83.1%。两者相比,P<0.01;中晚期(Ⅲ-Ⅳ期)的CTC检出数量与早期(Ⅰ-Ⅱ期)相比,P<0.01,具有统计学差异。结论微流控平台技术对CTC的捕获效率较高,微流控平台技术对于NSCLC早期诊断明显优于常规肿瘤标记物检测。
Objective Through the microfluidic platform to detection the circulation cell(Circulating Tumor cell,CTC)of non-small cell lung cancer(Non-small cell lung cancer,NSCLC)in patients and compared with the conventional Tumor markers detection,discusses the feasibility of the CTC detection for NSCLC preoperative auxiliary diagnosis.Methods Celltracker CMFDA staining was used to label tumor cells,cell incorporation and cell recovery were calculated.Collected the blood samples from 65 cases of clinical diagnosis of NSCLC patients,detected by the CTC detection and chemiluminescence detection.And then analyzed the results of two methods.Results The CTC capture efficiency of the microfluidic platform was 85.0±1.5%.In the samples of 65 cases of NSCLS patients,the detection numbers of traditional tumor markers was 34 cases,with a detection rate of 52.3%,and the detection rate of CTC was 83.1%.The number of CTC detected in the middle and late stage(Ⅲ-Ⅳ)was lower than that in the early stage(Ⅰ-Ⅱ).The difference was significant(P<0.01).Conclusion The microfluidic platform has a higher capture efficiency for CTC,and the microfluidic platform is significantly better than the traditional tumor marker detection for early diagnosis of NSCLC.
作者
丁光贵
王小艳
万军
丁培堃
黄同海
DING Guang-gui;WANG Xiao-yan;WAN Jun(Department of Thoracic Surgery,Shenzhen518020,China;不详)
出处
《中国实验诊断学》
2019年第10期1720-1723,共4页
Chinese Journal of Laboratory Diagnosis
关键词
微流控
非小细胞肺癌
肿瘤循环细胞
早期诊断
Microfluidic
Non-small cell lung cancer
Tumor circulating cells
early diagnosis
